Related Experiment Video
Updated: Jul 9, 2026

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria
Published on: February 28, 2025
[Biotransformation of mogroside III by human intestinal bacteria]
Xiu Wei Yang1, Jian Ye Zhang, Wei Xu
1Department of Natural Medicines, Peking University School of Pharmaceutical Sciences, Beijing 100083, China. xwyang@bjmu.edu.cn
Objective:
To investigate the biotransformation of mogroside III, one of the main chemical constituent in the fruits of Momordica grosvenori Swingle, by the crude enzymes of human intestinal bacteria, and determine the structure of biotransformation products and provide scientific basis for absorption evaluation of primary mogroside III in human intestine.
Methods:
The mogroside III was incubated with crude enzymes of human intestinal bacteria under the anaerobic environment and 37 degrees C condition to transform mogroside III. The biotransformation products were isolated and purified by silica gel column chromatography, and structurally determined by infra-red (IR) and nuclear magnetic resonance (NMR) spectrometry and mass spectroscopy (MS) techniques.
Results:
Mogroside III was converted to mogroside II(A1) and mogrol by successive deglycosylation at C-3 of the glucosyl group and C-24 of the gentiobiosyl group.
Conclusion:
The human intestinal bacteria showed potent ability to transform mogroside III to release secondary glycoside mogroside II(A1) and aglycone mogrol.
Related Concept Videos
Drug Biotransformation: Overview
Drug Biotransformation: Overview
Microbiota of the Large Intestine
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Microbiota of the Stomach and Small Intestine
Bioreactor Controls-III
